Botanix Pharmaceuticals : Updated Investor Presentation

For personal use only

12 July 2022

Updated Investor Presentation

Key highlights

• Release of updated corporate presentation to be used in a number of non-deal investor meetings scheduled this week
• The presentation includes:

1. an update on the accelerated FDA submission timetable of the New Drug Approval (NDA) for Sofpironium Bromide which is now planned for this quarter;

1. further insights into the market opportunity for Sofpironium Bromide; and

1. updated timetable for completion of rosacea (BTX 1702) Phase 1/2 clinical study and the canine dermatitis pilot study (BTX 1204A), which are now both fully enrolled and on target for completion in Q3 CY2022

Philadelphia PA and Phoenix USA, 12 July 2022: Clinical dermatology company, Botanix

Pharmaceuticals Limited (ASX: BOT, "Botanix" or "the Company"), is pleased to release an updated corporate presentation being used for a number of investor meetings scheduled this week.

The presentation includes an update on the FDA filing timetable for Sofpironium Bromide which has been accelerated and is now planned for this quarter, further insights into the market opportunity for Sofpironium Bromide, as well as an update on the Company's BTX 1702 Phase 1b/2 rosacea study and the BTX 1204A Phase 1b canine dermatitis study, which are on target for completion in Q3 CY2022.

Release authorised by

Vince Ippolito

President and Executive Chairman

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (USA) which is committed to the development of novel treatments for a range of common skin diseases. The Company has a mature dermatology pipeline with its first product, Sofpironium Bromide, for the treatment of primary axillary hyperhidrosis, planned to be filed for FDA in Q3 CY2022. The Company also has a pipeline of other products in late-stage clinical studies for the treatment of moderate to severe rosacea, dermatitis and acne respectively. Botanix is also developing a topical antimicrobial product for the eradication of bacteria on the skin surface, initially in patients who are undergoing hemodialysis.

For personal use only

Botanix leverages its proprietary drug delivery system (PermetrexTM) for direct skin delivery of active pharmaceuticals in all skin diseases, which is utilised in its existing development programs and is being explored with a view to being utilized in a number of other product opportunities. To learn more please visit: http://www.botanixpharma.com/

For more information, please contact:

General enquiries	Investor enquiries	Media enquiries
Corporate Communications	Hannah Howlett	Haley Chartres
Botanix Pharmaceuticals	WE Communications	H^CK
P: [phone]	P: [phone]	P: [phone]
[e-mail]	[e-mail]	[e-mail]

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, the expected timing and/or results of regulatory approvals and prospects of commercialising product candidates or research collaborations with its partners, including in Japan, the outcome and effects of Sofpironium Bromide and the market for Sofpironium Bromide and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's or its partners' ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's or its partners' ability to obtain marketing approvals for is product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

For personal use only

Investor Update

July 2022

Preparing to file first dermatology product for FDA approval in Q3 2022

1

onlyuse

personalBotanix:a leaderin topical drug development

For

Preparing to file for FDAapproval offirst productin $1.6 billion market

Pharmaceutical focus

New treatments for common skin diseases - such as excessive sweating (hyperhidrosis), rosacea and acne - as well as life- threatening bacterial infections

Topically driven

Targeting key indications with topical treatments that are safe, well tolerated and validated with clinical efficacy

World class team

US based team that have been responsible for more than 30 dermatology drug developments and launches

Sofpironium Bromide

First and only new drug for "primary axillary hyperhidrosis" (medical condition which results in excessive underarm sweating) already approved in Japan with partner1

Near-term catalysts

Upcoming filing for FDA approval for Sofpironium Bromide and data readouts from other pipeline products in 3Q CY2022

Source 1 : ASX release May 4 2022

2

For personal use only

World class board and	Developed, secured approval
for and commercialised over 30
management team	dermatology products

VINCE IPPOLITO	HOWIE MCKIBBON	DR PATRICIA WALKER	MATT CALLAHAN	DR BILL BOSCH
President and Executive Chairman	Chief Commercial Officer	Chief Medical Adviser	Board Executive Director	Board Executive Director
• COO of Anacor and Medicis; former President	• Former SVP Commercial of Dermavant, Anacor	• Former President and head R&D	• Serial founder and ex-investment director	• 30+ years experience in pharma industry
Dermavant; more than 17 years at Novartis.	and Medicis	Brickell Biotech	of two venture capital firms in life sciences	• Co-inventor of SoluMatrix™ drug delivery
• More than 35 years experience in pharma with	• 20+ years working in dermatology - launched	• Former CMO/CSO at Kythera, Inamed and	• Developed four products through FDA	technology and NanoCrystal® Technology
20+ years within dermatology	more than 15 brands and managed over 35	Allergan Medical responsible for multiple	approval and launch
	dermatology products	products including Botox and Tazorac

ANTHONY ROBINSON	DR JACK HOBLITZELL
VP of Development	SVP Pharmaceutical Development
• Recently Vice President R&D at Advicenne	• 30+ years leading world-class technical
• Senior leadership roles at Aquestive Therapeutics,	operations
Intrommune and Shire Pharmaceuticals	• Senior leadership roles at Assertio Therapeutics,
	Pfizer, King, Ivax and Teva

DR IRA LAWRENCE	DR CLARENCE YOUNG	LYNDA BYRNE
Clinical and Regulatory Adviser	Chief Medical Adviser, Antimicrobials	Commercial Adviser, Antimicrobials
• 30+ years of senior level leadership experience	• Recently Chief Medical Officer at	• Managing Partner BAL Pharma Consulting
within the global pharmaceutical and medical	Velicept Therapeutics	• Senior leadership roles at Motif Biosciences,
device industries	• Senior leadership roles at Iroko Pharmaceuticals,	Nabriva Therapeutics, Shire Abbot and BMS
• Former SVP R&D Medicis, Astellas and Fujisawa	Novartis, Protez and GlaxoSmithKline	3